文献速递糖尿病

新发1型糖尿病疾病修饰治疗试验中C肽与代谢结局:个体参与者Meta分析

C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis.
PubMed 文献 · Lancet Diabetes Endocrinol · 2023-11-03

该个体参与者Meta分析合并21项新发1型糖尿病疾病修饰治疗试验(1315名成人、1396名儿童),评估C肽与代谢结局的关系。阳性研究中6个月时C肽保留多24.8%与HbA1c低0.55%相关(p<0.0001),3个月即可检测到差异;横断面分析显示C肽保留改善55%与HbA1c低0.64%相关(p<0.0001)。作者认为保留β细胞功能的干预可改善代谢结局,支持C肽作为替代终点。

要点

  • 阳性研究中6个月时C肽保留多24.8%与HbA1c低0.55%相关(p<0.0001),3个月即可检测到差异。
  • 横断面分析中C肽保留改善55%与HbA1c低0.64%相关(p<0.0001)。
  • 初始C肽水平更高且保留更多者HbA1c改善更大;检测HbA1c、IDAAC和BETA-2评分所需样本量是C肽的2-3倍。

核心结论

  • 保留β细胞功能的干预可有效改善新发1型糖尿病的代谢结局,证实其作为胰岛素辅助治疗的潜力。
  • HbA1c改善与C肽保留程度直接成比例,支持将C肽作为临床试验的替代终点。

研究设计与样本

  • 个体参与者Meta分析,合并21项在1型糖尿病诊断后100天内开始的疾病修饰干预试验,共纳入1315名成人(18岁及以上)和1396名儿童(18岁以下)。
  • 评估终点为刺激后C肽曲线下面积、HbA1c、胰岛素使用、低血糖事件及复合评分(如胰岛素剂量调整A1c、每日总胰岛素、U/kg每日及BETA-2评分)。
  • 阳性研究定义为达到主要终点的研究;活性组与对照组结局差异采用Wilcoxon秩和检验评估。

主要发现

  • 治疗6个月后,阳性研究中C肽保留多24.8%与HbA1c低0.55%相关(p<0.0001),差异最早在3个月即可检测到。
  • 合并阳性和阴性研究的横断面分析与上述比例关系一致:C肽保留改善55%与HbA1c低0.64%相关(p<0.0001)。
  • 初始C肽水平更高且保留更多与HbA1c改善更大相关。
  • 对于HbA1c、IDAAC和BETA-2评分,样本量预测显示每组所需参与者数量是C肽的2-3倍才能在6个月时显示差异。
  • 检测低血糖减少受报告方法影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic outcomes in type 1 diabetes remain suboptimal. Disease modifying therapy to prevent β-cell loss presents an alternative treatment framework but the effect on metabolic outcomes is unclear. We, therefore, aimed to define the relationship between insulin C-peptide as a marker of β-cell function and metabolic outcomes in new-onset type 1 diabetes. METHODS: 21 trials of disease-modifying interventions within 100 days of type 1 diabetes diagnosis comprising 1315 adults (ie, those 18 years and older) and 1396 children (ie, those younger than 18 years) were combined. Endpoints assessed were stimulated area under the curve C-peptide, HbA1c, insulin use, hypoglycaemic events, and composite scores (such as insulin dose adjusted A1c, total daily insulin, U/kg per day, and BETA-2 score). Positive studies were defined as those meeting their primary endpoint. Differences in outcomes between active and control groups were assessed using the Wilcoxon rank test. FINDINGS: 6 months after treatment, a 24·8% greater C-peptide preservation in positive studies was associated with a 0·55% lower HbA1c (p<0·0001), with differences being detectable as early as 3 months. Cross-sectional analysis, combining positive and negative studies, was consistent with this proportionality: a 55% improvement in C-peptide preservation was associated with 0·64% lower HbA1c (p<0·0001). Higher initial C-peptide levels and greater preservation were associated with greater improvement in HbA1c. For HbA1c, IDAAC, and BETA-2 score, sample size predictions indicated that 2-3 times as many participants per group would be required to show a difference at 6 months as compared with C-peptide. Detecting a reduction in hypoglycaemia was affected by reporting methods. INTERPRETATION: Interventions that preserve β-cell function are effective at improving metabolic outcomes in new-onset type 1 diabetes, confirming their potential as adjuncts to insulin. We have shown that improvements in HbA1c are directly proportional to the degree of C-peptide preservation, quantifying this relationship, and supporting the use of C-peptides as a surrogate endpoint in clinical trials. FUNDING: JDRF and Diabetes UK.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Taylor PN, Collins KS, Lam A, et al. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. Lancet Diabetes Endocrinol. 2023. PMID: 37931637. doi:10.1016/S2213-8587(23)00267-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。